OR03-1 The Effect of Abaloparatide on Bone Mineral Density and Fracture Incidence in Postmenopausal Women with Osteoporosis and Osteoarthritis

Abaloparatide (ABL) is a novel, selective activator of the PTH1 receptor signaling pathway. In the 18-month Phase 3 ACTIVE study in women with postmenopausal osteoporosis (OP) (NCT01343004), ABL significantly increased bone mineral density (BMD), and decreased the risk of new vertebral (VF), nonvert...

Descripción completa

Detalles Bibliográficos
Autores principales: Lane, Nancy, Mitlak, Bruce, Weiss, Richard, Wang, Yamei, Valenzuela, Guillermo, Bilezikian, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2019
Materias:
Bone and Mineral Metabolism
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6554836/
http://dx.doi.org/10.1210/js.2019-OR03-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6554836/
http://dx.doi.org/10.1210/js.2019-OR03-1

Ejemplares similares